Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
minotaURO
2024-514979-17-04Phase 2Completed
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Feb 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cyclophosphamide in transitional cell carcinoma (TCC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Non-progressive rate at 6 months. Started Feb 2025; status: completed.
02
Drugs
pembrolizumabcyclophosphamide
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-514979-17-04.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514979-17-04.